COMP <GO>
SKIN vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
SkinHealth Systems Inc. (Class A) (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SKIN 0
— ABBV 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $9.94 (-2.07%) • MKT CAP: $66.0M
roic
-26.90%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SKIN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SKIN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.30% | 70.20% | -4.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -26.90% | 29.00% | -55.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -6.90% | 24.60% | -31.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -3.20% | 6.90% | -10.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -10.00% | 8.60% | -18.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.8 | 65.1 | -29.26 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $66.0M | $513.86B | -$513.79B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SKIN REV | ABBV REV | SKIN GROSS % | ABBV GROSS % | SKIN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $300.8M | $61.16B | 65.3% | 70.2% | $37.2M | $17.82B |
| FY 2024 | $334.3M | $56.33B | 54.5% | 70.0% | $15.4M | $17.83B |
| FY 2023 | $398.0M | $54.32B | — | — | $21.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SKIN // BETA —
ABBV // BETA 1.15